ADAMTS1: A matrix metalloprotease with angioinhibitory properties

Annals of the New York Academy of Sciences

Volumn 995, Issue , 2003, Pages 183-190

  Iruela Arispe, M Luisa ^a   Carpizo, Darren ^a   Luque, Alfonso ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Extracellular matrix; Tumor suppression

Indexed keywords

ANGIOGENESIS INHIBITOR; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PROTEIN ADAMTS1; PROTEIN METH1; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; CATALYSIS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; NEOVASCULARIZATION (PATHOLOGY); POINT MUTATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; XENOGRAFT;

EID: 0038129539     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb03221.x     Document Type: Conference Paper

References (33)

1. HANAHAN, D. & R.A. WEINBERG. 2000. The hallmarks of cancer. Cell 100: 57-70.
2. KERBEL, R. & J. FOLKMAN. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739.
3. ROSEN, L. 2000. Antiangiogenic strategies and agents in clinical trials. Oncologist 5(suppl. 1): 20-27.
4. O'REILLY, M.S. et al. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2: 689-692.
5. CARPIZO, D. & M.L. IRUELA-ARISPE. 2000. Endogenous regulators of angiogenesis - emphasis on proteins with thrombospondin-type I motifs. Cancer Metastasis Rev. 19: 159-165.
6. STUPACK, D.G. & D.A. CHERESH. 2002. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci. STKE 119: PE7.
7. GUTHEIL, J.C. et al. 2000. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin alphaV beta3. Clin. Cancer Res. 6: 3056-3061.
8. O'REILLY, M.S. et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
9. O'REILLY, M.S. et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
10. GOOD, D.J. et al. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87: 6624-6628.
11. IRUELA-ARISPE, M.L. et al. 1991. Thrombospondin exerts an antiangiogenic effect on tube formation by endothelial cells in vitro. Proc. Natl. Acad. Sci. USA 88: 5026-5030.
12. STREIT, M. et al. 2000. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J. 19: 3272-3282.
13. TOLSMA, S.S. et al. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122: 497-511.
14. IRUELA-ARISPE, M.L. et al. 1999. Inhibition of angiogenesis by thrombospondin-1 is mediated by two independent regions within the type 1 repeats. Circulation 100: 1423-1431.
15. HAWIGHORST, T. et al. 2001. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J. 20: 2631-2640.
16. IRUELA-ARISPE, M.L. et al. 1999. Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors. Ann. N.Y. Acad. Sci. 886: 58-66.
17. VAZQUEZ, F. et al. 1999. METH1, a human ortholog of ADAMTS, and METH2 are members of a new family of proteins with angio-inhibitory activity. J. Biol. Chem. 274: 23349-23357.
18. KUNO, K. et al. 1997. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J. Biol. Chem. 272: 556-562.
19. CAL, S. et al. 2002. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283: 49-62.
20. LLAMAZARES, M. et al. 2003. Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON-domain. J. Biol. Chem. In press.
21. KUNO, K. et al. 1998. ADAMTS-I protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. J. Biol. Chem. 273: 13912-13917.
22. RODRIGUEZ-MANZANEQUE, J.C. et al. 2000. Characterization of Meth-1/Adamts-1 processing reveals two distinct active forms. J. Biol. Chem. 275: 33471-33479.
23. TORTORELLA, M. et al. 2000. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J. Biol. Chem. 275: 25791-25797.
24. FLANNERY, C.R. et al. 2002. Autocatalytic cleavage of ADAMTS-4 (aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J. Biol. Chem. 277: 42775-42780.
25. LUQUE, A. et al. 2003. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. In press.
26. GUPTA, K. et al. 1999. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3: 147-158.
27. HASHIMOTO, G. et al. 2002. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 277: 36288-36295.
28. RODRIGUEZ-MANZANEQUE, J.C. et al. 2002. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun. 293: 501-508.
29. RODRIGUEZ-MANZANEQUE, J.C. et al. 2001. Thrombospondin-I suppresses tumor growth by a novel mechanism that includes blockade of matrix metalloproteinase-9 activation. Proc. Natl. Acad. Sci. USA 98: 12485-12490.
30. IRUELA-ARISPE, M.L. et al. 1999. Anti-angiogenic domain of thrombospondin. In Angiogenesis in Health and Disease: Basic Mechanisms and Clinical Applications.
31. KUNO, K. et al. 2000. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. 478: 241-245.
32. SANDY, J.D. et al. 2001. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site which is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J. Biol. Chem. 276: 13372-13378.
33. SHINDO, T. et al. 2000. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J. Clin. Invest. 105: 1345-1352.